Mayne Pharma Group Limited (ASX:MYX) revealed a long-term supply agreement with Novast Laboratories Limited for 13 US generic oral contraceptive products, that includes five new products which were not previously marketed by Mayne.
Four of the additional products are FDA approved while one of the products is awaiting FDA approval. The products include two of the most prescribed oral contraceptives in the United States.
Post announcement on 6 July 2020, MYX quoted at A$0.435 climbed by 6.098% at AEST 11:54 AM.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.